OGM - Standard-of-Care in Blood Cancers The I
Post# of 81

The International Consortium for Optical Genome Mapping has ENDORSED Optical Genome Mapping as a new standard-of-care tool for diagnosing blood cancers. Published in the American Journal of Hematology, the expert consensus supports REPLACING OUTDATED METHODS like karyotyping and FISH with this modern, high-resolution approach.
The endorsement highlights Optical Genome Mapping's ability to detect hidden genomic variants, improve risk assessment, and support personalized treatment. Conditions like leukemia, myelodysplastic syndromes, and multiple myeloma are among those expected to benefit from earlier and more accurate diagnosis.

